Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon ß-1a (Avonex®)


A Multinational, Multicenter, Randomized, Parallel-Group Study Performed in Subjects With RRMS to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-Blind Design and a Reference Arm of Interferon ß-1a (Avonex®) in a Rater-Blinded Design.




The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 mg with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing MS injectable drug: Interferon ß-1a (Avonex®).

Study Status: Recruiting


Condition Intervention Phase
Multiple Sclerosis Drug: laquinimod
Drug: placebo
Drug: Interferon ß-1a (Avonex®)
Phase 3

Verified by Teva Pharmaceutical Industries August, 2008

Sponsored by: Teva Pharmaceutical Industries
Information provided by: Teva Pharmaceutical Industries identifier: NCT00605215

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Cleveland Clinic Foundation - Mellon Center - Neurology Dept
Cleveland, Ohio 44195-5244
United States

Douglas L. Vollmer., Principal Investigator
Per S Sorensen., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site